Clinical trial
Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases
NCT00106054 · Pfizer, Industry · Terminated
Key facts
| NCT number | NCT00106054 |
|---|---|
| Title | Neoadjuvant Colorectal Cancer With Unresectable Liver Metastases |
| Official title | An Open-Label, Multi-Center Phase II Trial of Neoadjuvant Irinotecan in Combination With Infusional 5-FU, Leucovorin (Folfiri) Plus Bevacizumab in Patients With Unresectable Hepatic-Only Metastases of Colorectal Carcinoma |
| Lead sponsor | Pfizer, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Neoplasms, Liver Neoplasms |
| Intervention type | Drug |
| Interventions | Combination therapy of irinotecan with 5-FU, leucovorin plus bevacizumab in the neoadjuvant setting. |
| Enrollment | 2 |
| Start date | Jan 1, 2006 |
| Primary completion | Sep 1, 2006 |
| Completion | Sep 1, 2006 |
| First posted | Mar 21, 2005 |
| Last update posted | Aug 27, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: